ELISA: 1: 10000approx. 1: 20000. WB: 1: 500approx. 1: 1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1,0 mg/mL
Buffer
PBS, pH ~7.2, 0.05 % Sodium Azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
The vasoactive intestinal peptide (VIP) and the pituitary adenylate cylaseactivating polypeptide (PACAP) belong to a superfamily of peptide hormones that include glucagon, secretin and growth hormone releasing hormone. The effects of VIP and PACAP are mediated by three G-protein coupled receptors, VPAC1, VPAC2 and the PACAP receptor (also designated PAC1-R). The VPAC receptors have equal affinities for VIP and PACAP, which stimulate the activation of adenylyl cyclase. Both VPAC1, a 47 kDa protein, and VPAC2, a 65 kDa protein, are abundantly expressed in brain and T cells, where they modulate neuronal differentiation and T cell activation, respectively. The PACAP receptor is a seven transmembrane protein that produces at least eight isoforms by alternative splicing. Each isoform is associated with a specific signaling pathway and a specific expression pattern. The PACAP receptor, which is thought to play an integral role in brain development, preferentially binds PACAP in order to stimulate a cAMP-protein kinase A signaling pathway.Synonyms: PACAP-R-2, PACAPR2, Pituitary adenylate cyclase-activating polypeptide type II receptor, VIP-R1, VIPR-1, VIPR1, Vasoactive intestinal polypeptide receptor 1